5701-87-1

Upstream product

• 79025-28-8 3,4-Dimethoxy-2-nitro-benzoic acid 
• 103387-35-5 4-(3,4-dimethoxy-2-nitro-benzylidene)-2-phenyl-4H-oxazol-5-one 
• 2698-69-3 4-formyl-2-methoxy-3-nitrophenyl acetate 
• 2450-26-2 2-nitrovanillin 
• 881-68-5 vanillin acetate 
• 55149-84-3 2-nitroveratraldehyde 
• 4667-74-7 3,4-dimethoxyphthalimide 

Downstream Products

• 854660-53-0 2-anilino-3,4-dimethoxy-benzoic acid 
• 518-90-1 3,4-dimethoxy-phthalic acid 
• 5690-01-7 2-amino-3,4-dihydroxy-benzoic acid 
• 71568-87-1 2-bromo-3,4-dimethoxybenzoic acid 
• 6299-67-8 2,3-dimethoxyaniline 
• 93-07-2 Veratric acid 
• 132185-19-4 methyl 2-bromo-3,4-dimetoxybenzoate 
• 79025-27-7 2-amino-3,4-dimethoxy-benzoic acid methyl ester 
• 19178-11-1 7,8-dimethoxyquinazolin-4(3H)-one 
• 861522-34-1 2-acetylamino-3,4-dimethoxy-benzoic acid 

Relevant academic research and scientific papers

Small-molecule phosphodiesterase probes: Discovery of potent and selective CNS-penetrable quinazoline inhibitors of PDE1

PDE1 is a family of calcium-activated, dual substrate phosphodiesterases expressed in both the CNS and periphery that play a role in the integration of intracellular calcium and cyclic nucleotide signaling cascades. Exploration of the potential in targeting this family of enzymes to treat neuropsychiatric disorders has been hampered by a lack of potent, selective, and brain penetrable PDE1 inhibitors. To identify such compounds we used high-throughput screening, structure-based design, and targeted synthetic chemistry to discover the 4-aminoquinazoline 7a (PF-04471141) and the 4-indanylquinazoline 27 (PF-04822163) each of which are PDE1 inhibitors that readily cross the blood brain barrier. These quinazoline-based PDE1-selective inhibitors represent valuable new tools to study the biological processes regulated by PDE1 and to begin to determine the potential therapeutic utility of such compounds to treat neuropsychiatric disorders.

Multisubstituted 1-hydroxy-9-acridones with anticancer activity

The present invention provides a compound having the structure: STR1 The present invention also provides a method for synthesizing a compound having the above-identified structure as well as the intermediate compounds produced according to that method. The present invention further provides a pharmaceutical composition comprising the above compounds. Lastly, the present invention provides a method of inhibiting growth of tumor cells.

Buttressing and Electronic Effects of meta- and para-Methoxy Substituents on the Configurational Stability of 5,7-Dihydro-1,11-dimethoxydibenzoxepine

Three methoxy-substituted 5,7-dihydrodibenzoxepines have been prepared, each in both enantiomeric forms: (-)- and (+)-5,7-dihydro-1,3,9,11-tetramethoxydibenzoxepine (12) starting from, respectively, (+)- and (-)-4,4',6,6'-tetramethoxydiphenic acid (16); (+)- and (-)-5,7-dihydro-1,2,10,11-tetramethoxydibenzoxepine (13) from, respectively, (+)- and (-)-5,5',6,6'-tetramethoxydiphenic acid (25); and (R)-(+)- and (S)-(-)-5,7-dihydro-1,2,3,9,10,11-hexamethoxydibenzoxepine (14) from, respectively, (R)-(+)- and (S)-(-)-4,4',5,5',6,6'-hexamethoxydiphenic acid (30).The previously unpublished resolutions of 4,4',6,6'-tetramethoxydiphenic acid (16) and 5,5',6,6'-tetramethoxydiphenic acid (25) are described.Racemisation parameters for the three 5,7-dihydrodibenzoxepines have been determined and are compared with those for 5,7-dihydro-1,11-dimethoxydibenzoxepine (11).The buttressing effects of the meta-methoxy substituents, and the electronic effects of the para-methoxy substituents on the optical stabilities of the 5,7-dihydrodibenzoxepines are discussed, as are the u.v., and 1H and 13C n.m.r. spectra of these bridged biphenyls.

Alkoxy-substituted-6-chloro-quinazoline-2,4-diones

2,4-Diaminoquinazolines of the formula STR1 wherein Y1 is hydrogen or chloro, Y2 is OR, Y3 is hydrogen or OR such that when Y1 is hydrogen, Y3 is OR and when Y1 is chloro, Y3 is hydrogen or OR, and the pharmaceutically acceptable salts thereof; R represents an alkyl group having from one to three carbon atoms; taken separately, R1 and R2 are each hydrogen, alkyl having from one to five carbon atoms, cycloalkyl having from three to eight carbon atoms, alkenyl or alkynyl each having from three to five carbon atoms or hydroxy substituted alkyl having from two to five carbon atoms, when taken together with the nitrogen atom to which they are attached R1 and R2 form a substituted or unsubstituted heterocyclic group optionally containing an atom of oxygen, sulfur or a second atom of nitrogen as a ring member; their use as antihypertensive agents, pharmaceutical compositions containing them and intermediates for their production.